STOCK TITAN

Amberjack group (INVX) details 25.4% Innovex stake and 5M-share resale

(Moderate)
(Neutral)
Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

Innovex International, Inc. is the subject of an amended Schedule 13D that updates the holdings and recent transactions of Amberjack Capital Partners and related funds. On August 6, 2026, several affiliated funds entered into an Underwriting Agreement with Barclays Capital Inc. covering the resale by these selling stockholders of 5,000,000 shares of Innovex common stock at $28.71 per share, which closed on August 10, 2026.

After this transaction, Amberjack Capital Partners and its associated vehicles may be deemed to beneficially own 17,757,322 shares of Innovex common stock, representing 25.4% of the 69,935,827 shares outstanding as of August 4, 2026. Individual funds within the structure report specific direct holdings, with Amberjack Capital Fund II holding 13,164,573 shares (18.8%) and Innovex Co-Invest Fund II holding 3,073,822 shares (4.4%). The filing also describes a Lock-up Agreement under which the selling stockholders agreed, with limited exceptions, not to transfer additional shares for 45 days after the final prospectus date without the underwriter’s consent.

Positive

  • None.

Negative

  • None.

Filing Explained

The completed stockholder resale did not add issuer shares or disclose company proceeds, while affiliated holders continued to report 25.4% beneficial ownership.

This Amendment No. 3 to Schedule 13D updates ownership reported by a holder above 5% and records an offering agreement dated August 6, 2026 that closed on August 10, 2026.

The 5,000,000 shares were sold by existing stockholders to Barclays at $28.71 per share; this is a resale rather than an issuer share issuance, so the filing does not disclose new company shares or company proceeds from the offering.

The reported 25.4% beneficial ownership attributed to Amberjack Capital Partners and related persons reflects affiliated ownership and control relationships. The underlying funds report sole voting and dispositive power over their respective holdings, rather than shared power.

Underwritten shares sold 5,000,000 shares Offered and sold by selling stockholders to Barclays Capital Inc. at $28.71 per share
Offering price $28.71 per share Price to the underwriter for Innovex common stock in the August 2026 offering
Shares outstanding 69,935,827 shares Innovex common stock outstanding as of August 4, 2026
Amberjack Capital Partners holdings 17,757,322 shares Beneficially owned Innovex shares; 25.4% of outstanding common stock
Amberjack Capital Fund II holdings 13,164,573 shares Directly held Innovex shares; 18.8% of outstanding common stock
Innovex Co-Invest Fund II holdings 3,073,822 shares Directly held Innovex shares; 4.4% of outstanding common stock
Lock-up period 45 days Duration after final prospectus during which selling stockholders agree not to transfer shares without consent
Underwriting Agreement financial
"entered into an Underwriting Agreement with Intervale Capital Fund II, L.P."
An underwriting agreement is a contract where a company selling new stocks or bonds hires financial firms to buy those securities and resell them to investors. It matters because the agreement sets the offering price, number of securities, fees and which party bears the risk if sales fall short—think of it as a promise that the sale will happen and a roadmap investors can use to understand how the new securities reach the market.
Lock-up Agreement financial
"the Underwriter entered into a lock-up agreement with the Selling Stockholders"
A lock-up agreement is a contract that prevents company insiders and early investors from selling their shares for a fixed period after a stock sale, often after an initial public offering. It matters to investors because it temporarily limits the number of shares that can hit the market, which can keep the share price steadier; when the lock-up ends, a sudden increase in available shares can create extra volatility, revealing insiders’ confidence or lack thereof.
beneficial owner financial
"may be deemed the beneficial owner of 17,757,322 shares of Common Stock"
A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.
sole power to vote or direct vote financial
"1. Sole power to vote or direct vote: 17,757,322"
dispositive power financial
"Sole power to dispose or direct the disposition: 17,757,322"
Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What ownership stake in Innovex International (INVX) does Amberjack Capital Partners report?

Amberjack Capital Partners may be deemed to beneficially own 17,757,322 shares of Innovex common stock, representing 25.4% of the company’s 69,935,827 shares outstanding as of August 4, 2026, through various affiliated funds and general partners.

How many Innovex (INVX) shares were sold in the August 2026 underwritten offering?

The selling stockholders agreed to sell 5,000,000 shares of Innovex common stock to Barclays Capital Inc. as underwriter at a price of $28.71 per share. The offering, involving multiple Amberjack- and Intervale-related funds, closed on August 10, 2026.

How many Innovex (INVX) shares does Amberjack Capital Fund II hold after the transaction?

Amberjack Capital Fund II beneficially owns 13,164,573 shares of Innovex common stock, representing 18.8% of the outstanding shares. It also has sole power to vote and dispose of all 13,164,573 of those shares, according to the Schedule 13D/A amendment.

What are the Innovex (INVX) holdings of Innovex Co-Invest Fund II and Innovex Co-Invest Fund?

Innovex Co-Invest Fund II beneficially owns 3,073,822 shares (4.4%) and Innovex Co-Invest Fund owns 728,498 shares (1.0%) of Innovex common stock. Each fund reports sole power to vote and dispose of its respective share position.

What lock-up restrictions apply to the Innovex (INVX) selling stockholders?

Under a Lock-up Agreement dated August 6, 2026, the selling stockholders agreed not to transfer Innovex common stock, or related underlying shares, for 45 days after the date of the final prospectus without prior written consent of the underwriter, subject to specified exceptions.

How many Innovex (INVX) shares are outstanding in this Schedule 13D/A?

The ownership percentages are based on 69,935,827 shares of Innovex common stock outstanding as of August 4, 2026, as reported in the company’s prospectus supplement filed on August 10, 2026 with the Securities and Exchange Commission.





457651107

(CUSIP Number)
Jason Turowsky
Amberjack Capital Partners, L.P., 4400 Post Oak Parkway, Suite 2760
Houston, TX, 77002
(281) 605-3900

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
08/06/2026

(Date of Event Which Requires Filing of This Statement)


If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




schemaVersion:


SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D


Amberjack Capital Fund II, L.P.
Signature:/s/ Jason Turowsky
Name/Title:Jason Turowsky / Partner of Amberjack Capital Associates II, LLC, the general partner of Amberjack Capital GP II, L.P., its general partner
Date:08/10/2026
Innovex Co-Invest Fund II, L.P.
Signature:/s/ Jason Turowsky
Name/Title:Jason Turowsky / Partner of Innovex Co-Invest Associates, LLC, the general partner of Innovex Co-Invest Fund II GP, L.P., its general partner
Date:08/10/2026
Innovex Co-Invest Fund, L.P.
Signature:/s/ Jason Turowsky
Name/Title:Jason Turowsky / Partner of Innovex Co-Invest Associates, LLC, the general partner of Innovex Co-Invest Fund GP, L.P., its general partner
Date:08/10/2026
Intervale Capital Fund II, L.P.
Signature:/s/ Jason Turowsky
Name/Title:Jason Turowsky / Partner of Intervale Capital Associates II, LLC, the general partner of Intervale Capital GP II, L.P., its general partner
Date:08/10/2026
Intervale Capital Fund II-A, L.P.
Signature:/s/ Jason Turowsky
Name/Title:Jason Turowsky / Partner of Intervale Capital Associates II, LLC, the general partner of Intervale Capital GP II, L.P., its general partner
Date:08/10/2026
Intervale Capital Fund III, L.P.
Signature:/s/ Jason Turowsky
Name/Title:Jason Turowsky / Partner of Intervale Capital Associates III, LLC, the general partner of Intervale Capital GP III, L.P., its general partner
Date:08/10/2026
Amberjack Capital GP II, L.P.
Signature:/s/ Jason Turowsky
Name/Title:Jason Turowsky / Partner of Amberjack Capital Associates II, LLC, its general partner
Date:08/10/2026
Innovex Co-Invest Fund II GP, L.P.
Signature:/s/ Jason Turowsky
Name/Title:Jason Turowsky / Partner of Innovex Co-Invest Associates, LLC, its general partner
Date:08/10/2026
Innovex Co-Invest Fund GP, L.P.
Signature:/s/ Jason Turowsky
Name/Title:Jason Turowsky / Partner of Innovex Co-Invest Associates, LLC, its general partner
Date:08/10/2026
Intervale Capital GP II, L.P.
Signature:/s/ Jason Turowsky
Name/Title:Jason Turowsky / Partner of Intervale Capital Associates II, LLC, its general partner
Date:08/10/2026
Intervale Capital GP III, L.P.
Signature:/s/ Jason Turowsky
Name/Title:Jason Turowsky / Partner of Intervale Capital Associates III, LLC, its general partner
Date:08/10/2026
Amberjack Capital Associates II, LLC
Signature:/s/ Jason Turowsky
Name/Title:Jason Turowsky / Partner
Date:08/10/2026
Innovex Co-Invest Associates, LLC
Signature:/s/ Jason Turowsky
Name/Title:Jason Turowsky / Partner
Date:08/10/2026
Interval Capital Associates II, LLC
Signature:/s/ Jason Turowsky
Name/Title:Jason Turowsky / Partner
Date:08/10/2026
Intervale Capital Associates III, LLC
Signature:/s/ Jason Turowsky
Name/Title:Jason Turowsky / Partner
Date:08/10/2026
Amberjack Capital Partners, L.P.
Signature:/s/ Jason Turowsky
Name/Title:Jason Turowsky / Partner of Amberjack Management, LLC, its general partner
Date:08/10/2026
Amberjack Management, LLC
Signature:/s/ Jason Turowsky
Name/Title:Jason Turowsky / Partner
Date:08/10/2026
Jason Turowsky
Signature:/s/ Jason Turowsky
Name/Title:Jason Turowsky / Self
Date:08/10/2026